WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) has shared an announcement.
WuXi AppTec Co., Ltd. has announced the completion of a significant transaction involving its subsidiaries, WuXi ATU (Ireland) Holding Limited and WuXi ATU (Hong Kong) Limited, which have sold their shares in WuXi Advanced Therapies Inc. and Oxford Genetics Limited to Altaris LLC. This transaction, valued at up to $150 million, includes a guarantee by WuXi AppTec International Holdings Limited for potential indemnity obligations, reflecting the company’s strategic focus on optimizing its operations and maintaining its commitment to providing uninterrupted cell therapy services.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. operates in the pharmaceutical and biotechnology industry, providing a range of services including cell therapy services, investment consultation, and management. The company focuses on ensuring the availability of life-saving treatments and supporting scientific advancements in drug development.
YTD Price Performance: 12.30%
Average Trading Volume: 5,329,467
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$190.4B
Find detailed analytics on 2359 stock on TipRanks’ Stock Analysis page.